Clinical Trials
7 trialsNCT02834013 2026-06-03
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT07124000 2026-06-01
DP-04
AstraZeneca
Recruiting
NCT01552434 2026-05-15
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT06673329 2026-05-13
Brodalumab in the Treatment of Immune-Related Adverse Events
Columbia University
Phase 1 Recruiting
NCT02012699 2026-05-05
iCaRe2
University of Nebraska
Recruiting
NCT05461430 2026-04-13
TraveraRTGx
Travera Inc
Completed
NCT03420963 2026-03-20
Donor Natural Killer Cells, Cyclophosphamide, and Etoposide in Treating Children and Young Adults With Relapsed or Refractory Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Terminated